Florida
|
26-2792552
|
|
(State or other jurisdiction of incorporation)
|
(I.R.S. Employer Identification Number)
|
60 Chastain Center Blvd., Suite 60 | ||
Kennesaw, GA
|
30144
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(678) 384-6720
|
||
(Registrant’s telephone number, including area code)
|
Large accelerated filer o
|
Accelerated filer o
|
Non-accelerated filer o
|
Smaller reporting company x
|
|||
(Do not check if a smaller reporting company)
|
Part I FINANCIAL INFORMATION | |||
Item 1 | Condensed Consolidated Financial Statements | ||
3 | |||
4 | |||
5 | |||
6 | |||
8 | |||
Item 2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 24 | |
Item 3 | Quantitative and Qualitative Disclosures About Market Risk | 32 | |
Item 4 | Controls and Procedures | 32 | |
Part II OTHER INFORMATION | |||
Item 1 | Legal Proceedings | 32 | |
Item 1A | Risk Factors | 33 | |
Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 33 | |
Item 3 | Defaults under Senior Securities | 33 | |
Item 4 | Mine Safety Disclosures | 33 | |
Item 5 | Other Information | 33 | |
Item 6 | Exhibits | 34 | |
Signatures | 35 |
ASSETS
|
||||||||
September 30,
2012 |
December 31,
|
|||||||
(unaudited)
|
2011
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 7,621,226 | $ | 4,112,326 | ||||
Accounts receivable, net
|
6,170,124 | 1,891,919 | ||||||
Inventory, net
|
1,802,335 | 712,602 | ||||||
Prepaid expenses and other current assets
|
546,715 | 164,664 | ||||||
Total current assets
|
16,140,400 | 6,881,511 | ||||||
Property and equipment, net of accumulated depreciation of $2,168,898 and $1,814,473, respectively
|
999,866 | 869,411 | ||||||
Goodwill
|
4,040,443 | 4,040,443 | ||||||
Intangible assets, net of accumulated amortization and impairments of $6,384,656 and $3,468,515, respectively
|
12,174,344 | 15,090,485 | ||||||
Deposits and other long term assets
|
180,428 | 214,342 | ||||||
Total assets
|
$ | 33,535,481 | $ | 27,096,192 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued expenses
|
$ | 3,750,350 | $ | 2,300,638 | ||||
Other current liabilities
|
78,634 | 6,620 | ||||||
Convertible line of credit with related party, net of unamortized discount of $217,678 and $46,746, respectively, plus accrued interest of $91,521 and $42,726, respectively
|
1,173,846 | 1,295,980 | ||||||
Convertible debt related to acquisition, net of unamortized discount of $170,509, plus accrued interest of $49,315
|
- | 1,128,806 | ||||||
Current portion of earn-out liability payable In MiMedx common stock
|
5,545,280 | 3,185,223 | ||||||
Total current liabilities
|
10,548,110 | 7,917,267 | ||||||
Earn-out liability payable in MiMedx common stock, net of current portion
|
- | 4,225,280 | ||||||
Convertible Senior Secured Promissory Notes, net of unamortized discount of $1,569,592 and $2,263,145, respectively, plus accrued interest of $63,133 and $7,732, respectively
|
3,493,540 | 2,744,587 | ||||||
Other liabilities
|
311,085 | 312,493 | ||||||
Total liabilities
|
14,352,735 | 15,199,627 | ||||||
Commitments and contingencies (Note 12)
|
- | - | ||||||
Stockholders' equity:
|
||||||||
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding
|
- | - | ||||||
Common stock; $.001 par value; 110,000,000 shares authorized; 86,792,175 issued and 86,742,175 outstanding for 2012 and 74,306,895 issued and 74,256,895 outstanding for 2011
|
86,792 | 74,307 | ||||||
Additional paid-in capital
|
87,199,392 | 73,868,604 | ||||||
Treasury stock (50,000 shares at cost)
|
(25,000 | ) | (25,000 | ) | ||||
Accumulated deficit
|
(68,078,438 | ) | (62,021,346 | ) | ||||
Total stockholders' equity
|
19,182,746 | 11,896,565 | ||||||
Total liabilities and stockholders' equity
|
$ | 33,535,481 | $ | 27,096,192 |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
REVENUES:
|
||||||||||||||||
Net sales
|
$ | 7,954,046 | $ | 2,152,094 | $ | 16,544,110 | $ | 5,124,980 | ||||||||
OPERATING COSTS AND EXPENSES:
|
||||||||||||||||
Cost of products sold
|
1,425,336 | 886,510 | 3,499,117 | 2,441,568 | ||||||||||||
Research and development expenses
|
838,690 | 561,545 | 1,748,847 | 2,315,721 | ||||||||||||
Selling, general and administrative expenses
|
6,206,251 | 2,356,396 | 12,561,257 | 7,692,831 | ||||||||||||
Impairment of intangible assets
|
1,798,495 | - | 1,798,495 | - | ||||||||||||
Fair value adjustment of earn-out liability
|
1,320,000 | - | 1,320,000 | - | ||||||||||||
LOSS FROM OPERATIONS
|
(3,634,726 | ) | (1,652,357 | ) | (4,383,606 | ) | (7,325,140 | ) | ||||||||
OTHER INCOME (EXPENSE), net
|
||||||||||||||||
Financing expense associated with the debt discount recognized in connection with the senior secured promissory notes
|
(439,064 | ) | (80,689 | ) | (1,222,290 | ) | (214,206 | ) | ||||||||
Interest expense, net
|
(145,582 | ) | (32,677 | ) | (451,196 | ) | (77,445 | ) | ||||||||
LOSS BEFORE INCOME TAXES
|
(4,219,372 | ) | (1,765,723 | ) | (6,057,092 | ) | (7,616,791 | ) | ||||||||
Income taxes
|
- | - | - | - | ||||||||||||
NET LOSS
|
$ | (4,219,372 | ) | $ | (1,765,723 | ) | $ | (6,057,092 | ) | $ | (7,616,791 | ) | ||||
Net loss per common share
|
||||||||||||||||
Basic and diluted
|
$ | (0.05 | ) | $ | (0.02 | ) | $ | (0.07 | ) | $ | (0.11 | ) | ||||
Shares used in computing net loss per common share
|
||||||||||||||||
Basic and diluted
|
84,493,164 | 73,767,674 | 84,091,014 | 72,082,605 |
Convertible
Preferred Stock |
Common Stock
|
Additional
Paid-in |
Treasury
|
Accumulated
|
||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Stock
|
Deficit
|
Total
|
|||||||||||||||||||||||||
Balances, December 31, 2011
|
- | $ | - | 74,306,895 | $ | 74,307 | $ | 73,868,604 | $ | (25,000 | ) | $ | (62,021,346 | ) | $ | 11,896,565 | ||||||||||||||||
Employee share-based compensation expense
|
- | - | - | - | 1,432,627 | - | - | 1,432,627 | ||||||||||||||||||||||||
Other share-based compensation expense
|
- | - | - | - | 323,042 | - | - | 323,042 | ||||||||||||||||||||||||
Exercise of stock options
|
- | - | 719,000 | 719 | 884,315 | - | - | 885,034 | ||||||||||||||||||||||||
Exercise of warrants
|
- | - | 7,857,266 | 7,857 | 5,917,682 | - | - | 5,925,539 | ||||||||||||||||||||||||
Repurchase warrants
|
- | - | - | - | (568 | ) | - | - | (568 | ) | ||||||||||||||||||||||
Cashless exercise of warrants
|
- | - | 216,085 | 216 | (216 | ) | - | - | - | |||||||||||||||||||||||
Common stock issued for accrued director fees
|
- | - | 167,086 | 167 | 184,486 | - | - | 184,653 | ||||||||||||||||||||||||
Common stock issued for earn-out liability
|
- | - | 2,632,576 | 2,633 | 3,182,590 | - | - | 3,185,223 | ||||||||||||||||||||||||
Discount on benefical conversion feature recognized on line of credit with related party
|
- | - | - | - | 514,456 | - | - | 514,456 | ||||||||||||||||||||||||
Common stock issued for acquisition note
|
- | - | 893,267 | 893 | 892,374 | - | - | 893,267 | ||||||||||||||||||||||||
Net loss for the peiod
|
- | - | - | - | - | - | (6,057,092 | ) | (6,057,092 | ) | ||||||||||||||||||||||
Balances, September 30, 2012
|
- | $ | - | 86,792,175 | $ | 86,792 | $ | 87,199,392 | $ | (25,000 | ) | $ | (68,078,438 | ) | $ | 19,182,746 |
Nine Months Ended September 30,
|
||||||||
2012
|
2011
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$ | (6,057,092 | ) | $ | (7,616,791 | ) | ||
Adjustments to reconcile net loss to net cash flows from operating activities:
|
||||||||
Depreciation
|
354,425 | 330,851 | ||||||
Amortization of intangible assets
|
1,117,646 | 1,001,931 | ||||||
Impairment of intangible assets
|
1,798,495 | - | ||||||
Amortization of debt discount and deferred financing costs
|
1,222,289 | 246,807 | ||||||
Employee share-based compensation expense
|
1,432,627 | 1,032,261 | ||||||
Other share-based compensation expense
|
323,042 | 285,154 | ||||||
Change in fair value of earn-out liability
|
1,320,000 | - | ||||||
Increase (decrease) in cash resulting from changes in (net of effects of acquisition):
|
||||||||
Accounts receivable
|
(4,278,205 | ) | (818,102 | ) | ||||
Inventory
|
(1,089,733 | ) | (150,479 | ) | ||||
Prepaid expenses and other current assets
|
(382,051 | ) | (161,010 | ) | ||||
Other assets
|
19,213 | (48,174 | ) | |||||
Accounts payable and accrued expenses
|
1,446,864 | 833,013 | ||||||
Accrued interest
|
312,775 | 65,281 | ||||||
Other liabilities
|
(1,408 | ) | (9,825 | ) | ||||
Net cash flows from operating activities
|
(2,461,113 | ) | (5,009,083 | ) | ||||
Cash flows from investing activities:
|
||||||||
Purchases of equipment
|
(401,864 | ) | (417,900 | ) | ||||
Cash paid for acquisition, net of cash aquired of $33,583
|
- | (466,417 | ) | |||||
Net cash flows from investing activities
|
(401,864 | ) | (884,317 | ) | ||||
Cash flows from financing activities:
|
||||||||
Proceeds from exercise of warrants
|
5,925,539 | - | ||||||
Proceeds from exercise of stock options
|
885,034 | 295,753 | ||||||
Repayment of convertible debt related to acquisition
|
(427,126 | ) | - | |||||
Repayment of equipment lease
|
(11,002 | ) | - | |||||
Repurchase of warrants
|
(568 | ) | - | |||||
Proceeds from line of credit with related party
|
- | 1,300,000 | ||||||
Repayment of line of credit
|
- | (99,000 | ) | |||||
Repayment of note payable
|
- | (50,671 | ) | |||||
Proceeds from sale of common stock and warrants and common stock with registration rights, net
|
- | 3,743,588 | ||||||
Net cash flows from financing activities
|
6,371,877 | 5,189,670 | ||||||
Net change in cash
|
3,508,900 | (703,730 | ) | |||||
Cash, beginning of period
|
4,112,326 | 1,340,922 | ||||||
Cash, end of period
|
$ | 7,621,226 | $ | 637,192 | ||||
Supplemental disclosure of cash flow information:
|
||||||||
Cash paid for interest
|
$ | 8,738 | $ | 4,842 | ||||
Cash paid for income taxes
|
$ | - | $ | - |
*
|
the Company issued 167,086 shares of stock valued at $184,653 for accrued Director's fees
|
*
|
the Company issued 167,183 shares of stock for cashless exercise of warrants
|
*
|
the Company recognized $9,537 in deferred financing costs related to placement agent warrants issued in conjunction with the convertible Senior Promissory Notes
|
*
|
the Company recognized a beneficial conversion feature valued at $514,456 related to the vested contingent warrants on the line of credit with related party
|
*
|
the Company issued 2,632,576 shares of stock valued at $3,185,223 for payment of the 2011 Earn-out liability related to its acquisition of Surgical Biologics
|
*
|
the Company acquired equipment under a capital lease in the amount of $83,016
|
*
|
the Company issued 893,267 shares of stock valued at $893,267 for payment of the Convertible Secured Promissory Notes related to the acquisition of Surgical Biologics
|
*
|
the Company converted its outstanding convertible debt and accrued interest to equity by issuing406,664 shares of common stock
|
*
|
the Company issued 5,250,000 shares of stock valued at $7,087,500 in conjunction with itsacquisition of Surgical Biologics, LLC
|
*
|
the Company recognized a beneficial conversion feature valued at $437,500 related to theconvertible debt of $1,250,000 issued with regard to its acquisition of Surgical Biologics
|
*
|
the Company recognized a beneficial conversion feature valued at $80,000 related to theconvertible Line of Credit with a related party
|
1.
|
Basis of Presentation
|
2.
|
Significant accounting policies
|
Three months ended September 30,
|
Nine months ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Net loss
|
$ | (4,219,372 | ) | $ | (1,765,723 | ) | $ | (6,057,092 | ) | $ | (7,616,791 | ) | ||||
Denominator for basic earnings per share - weighted average shares
|
84,493,164 | 73,767,674 | 84,091,014 | 72,082,605 | ||||||||||||
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)
|
— | — | — | — | ||||||||||||
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
|
84,493,164 | 73,767,674 | 84,091,014 | 72,082,605 | ||||||||||||
Loss per common share - basic and diluted
|
$ | (0.05 | ) | $ | (0.02 | ) | $ | (0.07 | ) | $ | (0.11 | ) |
(a)
|
Securities outstanding that were excluded from the computation, because they would have been anti-dilutive are as follows:
|
September 30, 2012
|
September 30, 2011
|
|||||||
Outstanding Stock Options
|
12,642,833 | 10,355,000 | ||||||
Outstanding Warrants
|
3,241,668 | 8,096,417 | ||||||
Convertible Debt, promissory notes
|
5,313,133 | — | ||||||
Convertible Line of Credit with Related Party
|
1,391,524 | 1,300,000 | ||||||
Convertible Debt, Acquisition
|
— | 1,250,000 | ||||||
22,589,158 | 21,001,417 |
3.
|
Liquidity and management’s plans
|
4.
|
Acquisition of Surgical Biologics, LLC
|
Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
|
||||
Contingent Liability for
Accrued Earn-out |
||||
Beginning balance at January 1, 2012
|
$ | 7,410,503 | ||
Common stock issued on earn-out
|
(3,185,223 | ) | ||
Total remeasurement adjustments:
|
||||
(Gains) or losses included in earnings
|
1,320,000 | |||
Ending balance at September 30, 2012
|
$ | 5,545,280 |
Value of 5,250,000 shares issued at $1.35 per share
|
$ | 7,087,500 | ||
Cash paid at closing
|
350,000 | |||
Cash retained for working capital
|
150,000 | |||
Assumed Debt
|
182,777 | |||
Convertible Secured Promissory Note
|
1,250,000 | |||
Fair value of earn-out
|
7,404,700 | |||
Total fair value of purchase price
|
$ | 16,424,977 | ||
Assets purchased:
|
||||
Tangible assets:
|
||||
Debt-free working capital
|
$ | 671,880 | ||
Other assets, net
|
385 | |||
Property, plant and equipment
|
72,866 | |||
745,131 | ||||
Intangible assets:
|
||||
Customer relationships
|
3,520,000 | |||
Supplier relationships
|
241,000 | |||
Patents and know-how
|
5,530,000 | |||
Trade names and trademarks
|
1,008,000 | |||
In-process research and development – liquid
|
2,160,000 | |||
In-process research and development – other
|
25,000 | |||
Licenses and permits
|
13,000 | |||
12,497,000 | ||||
Goodwill
|
3,182,846 | |||
Total Assets Purchased
|
$ | 16,424,977 |
Working capital:
|
||||
Cash
|
$ | 33,583 | ||
Prepaid Expenses
|
2,738 | |||
Accounts Receivable
|
181,087 | |||
License Receivable
|
340,000 | |||
Inventory
|
347,106 | |||
Accounts payable and accrued expenses
|
(196,101 | ) | ||
Deferred rent and customer deposits
|
(36,533 | ) | ||
Debt-free working capital
|
671,880 | |||
Current portion of debt
|
(62,590 | ) | ||
Long-term debt
|
(21,187 | ) | ||
Line of credit
|
(99,000 | ) | ||
Net working capital
|
$ | 489,103 | ||
Deposits
|
$ | 16,582 | ||
Deferred rent (non-current)
|
(16,197 | ) | ||
$ | 385 |
Intangible asset:
|
Estimated useful
life (in years)
|
Customer relationships
|
14
|
Supplier relationships
|
14
|
Patents and know-how
|
14
|
Trade names and trademarks
|
indefinite
|
In-process research and development – liquid
|
indefinite
|
In-process research and development – other
|
indefinite
|
Licenses and permits
|
3
|
5.
|
Inventories
|
September 30, 2012
|
December 31, 2011
|
|||||||
Raw materials
|
$ | 135,123 | $ | 95,288 | ||||
Work in process
|
1,059,772 | 308,763 | ||||||
Finished goods
|
662,295 | 361,007 | ||||||
$ | 1,857,190 | $ | 765,058 | |||||
Reserve for obsolescence
|
(54,855 | ) | (52,456 | ) | ||||
Inventory, net
|
$ | 1,802,335 | $ | 712,602 |
6.
|
Property and equipment
|
September 30, 2012
|
December 31, 2011
|
|||||||
Leasehold improvements
|
$ | 990,127 | $ | 925,086 | ||||
Lab and clean room equipment (a)
|
1,760,427 | 1,463,144 | ||||||
Furniture and office equipment (a)
|
418,210 | 295,654 | ||||||
3,168,764 | 2,683,884 | |||||||
Less accumulated depreciation
|
(2,168,898 | ) | (1,814,473 | ) | ||||
$ | 999,866 | $ | 869,411 |
|
(a)
|
The table above includes reclassifications of production equipment previously included in the furniture and office equipment category.
|
7.
|
Intangible assets and royalty agreement
|
|
Intangible assets activity is summarized as follows:
|
September 30, 2012
|
December 31, 2011
|
|||||||||||||||||||||||||||||
Weighted
Average |
Gross
Carrying |
Impairment
Adjustment |
Accumulated
Amortization |
Net
Carrying |
Gross
Carrying |
Accumulated
Amortization |
Net
Carrying |
|||||||||||||||||||||||
Intangible assets subject to amortization:
|
||||||||||||||||||||||||||||||
License-Shriners Hsp for Children & USF Research (a)
|
10 years
|
$ | 996,000 | $ | (562,733 | ) | $ | 433,267 | $ | 996,000 | $ | (488,033 | ) | $ | 507,967 | |||||||||||||||
License - SaluMedica LLC Spine Repair (b)
|
10 years
|
2,399,000 | (851,676 | ) | (1,535,586 | ) | 11,738 | 2,399,000 | (1,313,573 | ) | 1,085,427 | |||||||||||||||||||
License - Polyvinyl Alcohol Cryogel (c)
|
10 years
|
2,667,000 | (946,819 | ) | (1,203,170 | ) | 517,011 | 2,667,000 | (998,932 | ) | 1,668,068 | |||||||||||||||||||
Customer Relationships (d)
|
14 years
|
3,520,000 | (440,000 | ) | 3,080,000 | 3,520,000 | (251,429 | ) | 3,268,571 | |||||||||||||||||||||
Supplier Relationships (d)
|
14 years
|
241,000 | (30,125 | ) | 210,875 | 241,000 | (17,215 | ) | 223,785 | |||||||||||||||||||||
Patents & Know-How (d)
|
14 years
|
5,530,000 | (691,250 | ) | 4,838,750 | 5,530,000 | (395,000 | ) | 5,135,000 | |||||||||||||||||||||
Micronized Processing Know-How (d)
|
14 years
|
2,160,000 | (115,714 | ) | 2,044,286 | 2,160,000 | — | 2,160,000 | ||||||||||||||||||||||
Licenses/Permits (d)
|
3 years
|
13,000 | (7,583 | ) | 5,417 | 13,000 | (4,333 | ) | 8,667 | |||||||||||||||||||||
$ | 17,526,000 | $ | (1,798,495 | ) | $ | (4,586,161 | ) | $ | 11,141,344 | $ | 17,526,000 | $ | (3,468,515 | ) | $ | 14,057,485 | ||||||||||||||
Intangible assets not subject to amortization: | ||||||||||||||||||||||||||||||
Trade Names/Trademarks (d)
|
indefinite
|
1,008,000 | — | 1,008,000 | 1,008,000 | — | 1,008,000 | |||||||||||||||||||||||
In-process Research & Development-Other (d)
|
indefinite
|
25,000 | — | 25,000 | 25,000 | — | 25,000 | |||||||||||||||||||||||
$ | 18,559,000 | $ | (1,798,495 | ) | $ | (4,586,161 | ) | $ | 12,174,344 | $ | 18,559,000 | $ | (3,468,515 | ) | $ | 15,090,485 |
|
(a)
|
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. The acquisition price of this license was a one-time fee of $100,000 and 1,120,000 shares of common stock valued at $896,000 (based upon the estimated fair value of the common stock on the transaction date). Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products.
|
|
(b)
|
License from SaluMedica, LLC (SaluMedica) for the use of certain developed technologies related to spine repair. This license was acquired through the acquisition of SpineMedica Corp.
|
|
(c)
|
On March 31, 2008, the Company entered into a license agreement for the use of certain developed technologies related to surgical sheets made of polyvinyl alcohol cryogel. The acquisition price of the asset was 400,000 shares of common stock valued at $2,596,000 (based upon the closing price of the common stock on the transaction date). The agreement also provides for the issuance of an additional 600,000 shares upon the Company meeting certain milestones related to future sales. On December 31, 2009, the Company completed the sale of its first commercial product and met its first milestone under this agreement. As a result, the Company issued an additional 100,000 shares of common stock to the licensor valued at $71,000. At September 30, 2012 and 2011, there are no additional amounts accrued for this obligation due to its contingent nature.
|
|
(d)
|
On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.
|
Year ending December 31,
|
Estimated
Amortization
Expense
|
|||
2012 (a)
|
$ | 262,595 | ||
2013
|
1,050,380 | |||
2014
|
1,046,047 | |||
2015
|
1,022,651 | |||
2016
|
976,998 | |||
Thereafter
|
6,782,673 | |||
$ | 11,141,344 |
|
(a)
|
Estimated amortization expense for the year ending December 31, 2012 includes only amortization to be recorded after September 30, 2012.
|
8.
|
Debt
|
Convertible Line
of Credit with
Related Party
|
Convertible
Senior Secured
Promissory Note
|
Total
|
||||||||||
Face Value of Note
|
$ | 1,300,000 | $ | 5,000,000 | $ | 6,300,000 | ||||||
Due date | (a) |
12/31/2012
|
(b) |
12/31/2013
|
||||||||
Annual Interest rate
|
5 | % | 5 | % | ||||||||
Contingent warrants issued at inception (c):
|
||||||||||||
First Contingent Warrants
|
(d) | 325,000 | (e) | 1,250,000 | 1,575,000 | |||||||
Second Contingent Warrants
|
(f) | 325,000 | (f) | 1,250,000 | 1,575,000 | |||||||
Total Contingent Warrants
|
650,000 | 2,500,000 | 3,150,000 | |||||||||
Warrants as of September 30, 2012:
|
||||||||||||
First Contingent Warrants - Vested
|
(d) | (325,000 | ) | (e) | (1,250,000 | ) | (1,575,000 | ) | ||||
Second Contingent Warrants - Voided
|
(f) | (325,000 | ) | (f) | (1,250,000 | ) | (1,575,000 | ) | ||||
Contingent Warrants Outstanding as of September 30, 2012
|
||||||||||||
First Contingent Warrants
|
— | — | — | |||||||||
Second Contingent Warrants
|
— | — | — | |||||||||
Total Contingent Warrants Outstanding as of September 30, 2012
|
$ | — | $ | — | $ | — | ||||||
Weighted average exercise price of warrants
|
$ | 0.01 | $ | 0.01 |
(a)
|
The initial termination date of the Credit Agreement is December 31, 2012 and the Company may elect to extend the termination date until December 31, 2013 upon payment of an extension fee of 5% of the outstanding principle balance or $65,000.
|
(b)
|
Unless the Company has repaid the applicable lender’s Notes in full prior to December 31, 2012, the Company must pay to each lender an additional interest payment in the amount of five percent (5%) of the aggregate outstanding principal amount of such lender’s Notes as of December 31, 2012.
|
(c)
|
The Contingent Warrants have a term of five years from the date of issuance; however each is subject to automatic terminations as defined in the First Contingent Warrant and Second Contingent Warrant terms. The shares of Common Stock issuable upon exercise of the Contingent Warrants do not carry registration rights and may be exercised on a “cashless” basis. In the event of a change in control transaction on or prior to the First Measurement Date, then the Contingent Warrants shall be exercisable immediately prior to the closing of such change in control transaction. In the event (i) of a change in control transaction after the First Measurement Date and on or prior to the Second Measurement Date and (ii) the per share value of the consideration received by the holders of Common Stock in such change in control transaction is at least $1.75, the Second Contingent Warrant shall be null and void. If the value of the per share consideration received by the holders of Common Stock in such transaction is less than $1.75, the Second Contingent Warrant shall be exercisable immediately prior to the closing of such change in control transaction.
|
(d)
|
The First Contingent Warrant, (the “First Contingent Warrant”) is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company’s Gross Revenue as reported in the Company’s Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the “First Measurement Date”) the closing trading price of the Stock is at least $1.50 per share for ten or more consecutive trading days. As of March 31, 2012, the First Contingent Warrants vested due to the Company’s Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011, and due to the closing trading price of the stock not equaling or exceeding $1.50 per share for ten or more consecutive trading days.
|
(e)
|
The First Contingent Warrant, (the “First Contingent Warrant”) is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the First Contingent Warrant shall only be exercisable if the Company’s Gross Revenue as reported in the Company’s Audited Financial Statements for the year ended December 31, 2011, do not equal or exceed $11,500,000. As of December 31, 2011, the First Contingent warrants vested due to the Company’s Gross Revenue not exceeding $11,500,000 for the year ended December 31, 2011.
|
(f)
|
The Second Contingent Warrant, (the “Second Contingent Warrant”) is issued to each investor to purchase 25% of the number of shares of Stock purchased, at an exercise price of $0.01 per share, provided that the Second Contingent Warrant shall only be exercisable if the Company’s Gross Revenue as reported in the Company’s Audited Financial Statements for the year ended December 31, 2012, do not equal or exceed $31,150,000 and further provided that such Warrant shall be null and void in the event that prior to issuance of such Audited Financial Statements (the “Second Measurement Date”) the closing trading price of the Stock is at least $1.75 per share for ten or more consecutive trading days. The second contingent warrants were voided on July 3, 2012 which was the tenth consecutive trading day where the closing price of the Company stock was at least $1.75.
|
9.
|
Common Stock Placements
|
10.
|
Equity
|
Number of
Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Term
(in years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding at January 1, 2012
|
10,333,583 | $ | 1.17 | |||||||||||||
Granted
|
4,203,000 | $ | 1.61 | |||||||||||||
Exercised
|
(718,998 | ) | $ | 1.23 | ||||||||||||
Unvested options forfeited
|
(225,504 | ) | $ | 1.17 | ||||||||||||
Vested options expired
|
(949,248 | ) | $ | 1.55 | ||||||||||||
Outstanding at September 30, 2012
|
12,642,833 | $ | 1.28 | 8.0 | $ | 21,096,473 | ||||||||||
Vested at September 30, 2012
|
4,953,133 | $ | 1.06 | 6.4 | $ | 9,362,856 | ||||||||||
Vested and expected to vest at September 30, 2012 (a)
|
12,430,387 | $ | 1.27 | 8.0 | $ | 20,823,954 |
(a)
|
Includes forfeiture adjusted unvested shares.
|
Options Outstanding
|
Options Exercisable
|
||||||||||||||||||||
Range of Exercise Prices
|
Number
outstanding
|
Weighted-
Average
Remaining
Contractual
Term
(in years)
|
Weighted-
Average
Exercise Price
|
Number
Exercisable
|
Weighted-
Average
Exercise Price
|
||||||||||||||||
$0.50 | 505,000 | 2.2 | $ | 0.50 | 505,000 | $ | 0.50 | ||||||||||||||
$0.65 - $1.00 | 2,097,500 | 6.6 | $ | 0.72 | 1,946,666 | $ | 0.72 | ||||||||||||||
$1.04 - $1.80 | 8,840,333 | 8.5 | $ | 1.29 | 2,471,467 | $ | 1.43 | ||||||||||||||
$1.99 - $2.84 | 1,200,000 | 9.6 | $ | 2.50 | 30,000 | $ | 2.40 | ||||||||||||||
12,642,833 | 8.0 | $ | 1.28 | 4,953,133 | $ | 1.06 |
Nine months ended September 30,
|
||||||||
2012
|
2011
|
|||||||
Expected volatility
|
45.75 - 64.3 | % | 57.3 - 57.8 | % | ||||
Expected life (in years)
|
6 | 6 | ||||||
Expected dividend yield
|
— | — | ||||||
Risk-free interest rate
|
0.62% - 1.62 | % | 0.93% - 2.24 | % |
Number of
Warrants
|
|
Weighted-
Average
Exercise
Price per
Warrant
|
Number of
Contingent
Warrants
|
Weighted-
Average
Exercise
Price per
Contingent
Warrant
|
||||||||||||
Warrants outstanding at January 1, 2012
|
9,388,817 | $ | 1.00 | 5,245,484 | $ | 0.01 | ||||||||||
Warrants issued:
|
||||||||||||||||
Vested contingent warrants related to private placement of common stock
|
1,672,743 | $ | 0.01 | (1,672,743 | ) | $ | 0.01 | |||||||||
Vested contingent warrants related to line of credit with related party
|
325,000 | $ | 0.01 | (325,000 | ) | $ | 0.01 | |||||||||
Contingent warrants voided
|
— | — | (3,247,741 | ) | $ | 0.01 | ||||||||||
Warrants exercised:
|
||||||||||||||||
Contingent warrants related to convertible note
|
(1,329,687 | ) | $ | 0.01 | — | — | ||||||||||
Contingent warrants related to private placement of common stock
|
(1,476,365 | ) | $ | 0.01 | — | — | ||||||||||
Contingent warrants related to line of credit with related party
|
(325,000 | ) | $ | 0.01 | — | — | ||||||||||
Callable warrants
|
(3,288,733 | ) | $ | 1.50 | ||||||||||||
Other
|
(1,653,568 | ) | $ | 0.60 | ||||||||||||
Warrants redeemed for cashless exercises
|
(14,789 | ) | $ | 0.60 | — | — | ||||||||||
Repurchased callable warrants
|
(56,750 | ) (a) | $ | 1.50 | — | — | ||||||||||
Warrants outstanding at September 30, 2012
|
3,241,668 | $ | 1.04 | — |
(a)
|
The Company repurchased the callable warrants at $0.01 per share.
|
|
·
|
notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or
|
|
·
|
election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.
|
11.
|
Income taxes
|
12.
|
Contractual Commitments
|
12-month period ended September 30,
|
||||
2013
|
$ | 615,299 | ||
2014
|
256,516 | |||
Thereafter
|
72,907 | |||
$ | 944,722 |
13.
|
Subsequent Events
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
Three Months Ended September 30,
|
||||||||
Depreciation expense included in:
|
2012
|
2011
|
||||||
Cost of products sold
|
$ | 41,760 | $ | 25,594 | ||||
Research and development
|
29,804 | 31,480 | ||||||
Selling, general and administrative
|
51,370 | 41,915 | ||||||
$ | 122,934 | $ | 98,989 |
Three Months Ended September 30,
|
||||||||
Share-based compensation included in:
|
2012
|
2011
|
||||||
Cost of products sold
|
$ | 11,643 | $ | 17,549 | ||||
Research and development
|
70,754 | 44,830 | ||||||
Selling, General and administrative
|
587,072 | 223,359 | ||||||
$ | 669,469 | $ | 285,738 |
Three Months Ended September 30,
|
||||||||||||||||||||||||||||||||
2012
|
2011
|
|||||||||||||||||||||||||||||||
Amortization
of Debt
Discount
|
Accrued
Interest
|
Interest
Expense,
net
|
Total
|
Amortization
of Debt
Discount
|
Accrued
Interest
|
Interest
Expense,
net
|
Total
|
|||||||||||||||||||||||||
Convertible Line of Credit with Related Party
|
$ | 181,224 | $ | 16,384 | $ | — | $ | 197,608 | $ | 11,084 | $ | 16,384 | $ | — | $ | 27,468 | ||||||||||||||||
Convertible Debt related to acquisition
|
3,821 | 585 | — | 4,406 | 69,605 | 12,603 | — | 82,208 | ||||||||||||||||||||||||
Convertible Senior Secured Promissory Notes
|
248,854 | 126,027 | — | 374,881 | — | — | — | — | ||||||||||||||||||||||||
Deferred financing related to Senior Secured Promissory Notes
|
5,164 | — | — | 5,164 | — | — | — | — | ||||||||||||||||||||||||
Other
|
— | — | 2,586 | 2,586 | — | — | 3,690 | 3,690 | ||||||||||||||||||||||||
$ | 439,063 | $ | 142,996 | $ | 2,586 | $ | 584,645 | $ | 80,689 | $ | 28,987 | $ | 3,690 | $ | 113,366 |
Nine Months Ended September 30,
|
||||||||
Depreciation expense included in:
|
2012
|
2011
|
||||||
Cost of products sold
|
$ | 114,729 | $ | 78,350 | ||||
Research and development
|
90,491 | 90,694 | ||||||
Selling, general and administrative
|
149,206 | 161,808 | ||||||
$ | 354,426 | $ | 330,852 |
Nine Months Ended September 30,
|
||||||||
Share-based compensation included in:
|
2012
|
2011
|
||||||
Cost of products sold
|
$ | 65,132 | $ | 71,570 | ||||
Research and development
|
217,885 | 229,401 | ||||||
Selling, General and administrative
|
1,472,652 | 1,016,443 | ||||||
$ | 1,755,669 | $ | 1,317,414 |
Nine Months Ended September 30,
|
||||||||||||||||||||||||||||||||
2012
|
2011
|
|||||||||||||||||||||||||||||||
Amortization
of Debt
Discount
|
Accrued
Interest
|
Interest
Expense,
net
|
Total
|
Amortization
of Debt
Discount
|
Accrued
Interest
|
Interest
Expense,
net
|
Total
|
|||||||||||||||||||||||||
Convertible Line of Credit with Related Party
|
$ | 343,527 | $ | 48,794 | $ | — | $ | 392,321 | $ | 22,002 | $ | 26,342 | $ | — | $ | 48,344 | ||||||||||||||||
Convertible Debt related to acquisition
|
170,509 | 21,078 | — | 191,587 | 192,204 | 36,712 | — | 228,916 | ||||||||||||||||||||||||
Convertible Senior Secured Promissory Notes
|
693,552 | 373,973 | — | 1,067,525 | — | — | — | — | ||||||||||||||||||||||||
Deferred financing related to Senior Secured Promissory Notes
|
14,701 | — | — | 14,701 | — | — | — | — | ||||||||||||||||||||||||
Other
|
— | — | 7,351 | 7,351 | — | — | 14,391 | 14,391 | ||||||||||||||||||||||||
$ | 1,222,289 | $ | 443,845 | $ | 7,351 | $ | 1,673,485 | $ | 214,206 | $ | 63,054 | $ | 14,391 | $ | 291,651 |
Payments due by period
|
||||||||||||||||||||
Contractual Obligations
|
TOTAL
|
Less than 1
year
|
1-3 years
|
3-5 years
|
More than
5 years
|
|||||||||||||||
Convertible senior secured promissory notes
|
$ | 5,000,000 | — | $ | 5,000,000 | — | — | |||||||||||||
Convertible debt, line of credit with related party
|
1,300,000 | 1,300,000 | — | — | — | |||||||||||||||
Employment agreements
|
55,421 | 55,421 | — | — | — | |||||||||||||||
Operating lease obligations
|
607,169 | 374,025 | 233,144 | — | — | |||||||||||||||
Consulting agreements
|
187,132 | 90,853 | 96,279 | — | — | |||||||||||||||
Royalty payments
|
95,000 | 95,000 | — | — | — | |||||||||||||||
$ | 7,244,722 | $ | 1,915,299 | $ | 5,329,423 | — | — |
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2012
|
2011
|
2012
|
2011
|
|||||||||||||
Net Loss (Per GAAP)
|
$ | (4,219,370 | ) | $ | (1,765,723 | ) | $ | (6,057,092 | ) | $ | (7,616,791 | ) | ||||
Add back:
|
||||||||||||||||
Income Taxes
|
- | - | - | - | ||||||||||||
Financing expense associated with beneficial conversion of note payable issued in conjunction with acquisition
|
3,821 | 69,605 | 170,509 | 192,204 | ||||||||||||
Financing expense associated with beneficial conversion of Line of Credit with Related Party
|
181,224 | 11,084 | 343,527 | 22,002 | ||||||||||||
Financing expense associated with beneficial conversion of Senior Secured Promissory Note
|
248,854 | - | 693,552 | - | ||||||||||||
Other interest expense, net
|
150,746 | 32,677 | 465,897 | 77,445 | ||||||||||||
Depreciation Expense
|
122,934 | 98,989 | 354,425 | 330,851 | ||||||||||||
Amortization Expense
|
449,691 | 333,977 | 1,117,646 | 1,001,931 | ||||||||||||
Employee Share Based Compensation
|
554,136 | 222,792 | 1,432,627 | 1,028,801 | ||||||||||||
Other Share Based Compensation
|
115,333 | 62,946 | 323,042 | 288,614 | ||||||||||||
Impairment of Intangible Assets
|
1,798,495 | - | 1,798,495 | - | ||||||||||||
Fair Value Adjustment of Earn-out Liability
|
1,320,000 | - | 1,320,000 | - | ||||||||||||
Earnings/(Loss) Before Interest, Taxes, Depreciation, Amortization, Share-Based Compensation, Impairments and FV Adjustments
|
$ | 725,864 | $ | (933,653 | ) | $ | 1,962,628 | $ | (4,674,943 | ) |
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
Item 4.
|
Controls and Procedures
|
Item 1.
|
Legal Proceedings
|
Item 1A.
|
Risk Factors
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
Item 3.
|
Default Upon Senior Securities
|
Item 4.
|
Mine Safety Disclosures
|
Item 5.
|
Other Information
|
Item 6.
|
Exhibits
|
Exhibit
Number
|
Reference
|
Description
|
#
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
#
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
#
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
#
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
#
|
Filed herewith
|
November 13, 2012 | |||
|
By:
|
/s/ Michael J. Senken | |
Michael J. Senken | |||
Chief Financial Officer |
Date: November 13, 2012
|
/s/ Parker H. Petit
|
Parker H. Petit
|
|
Chief Executive Officer
|
Date: November 13, 2012
|
/s/ Michael J. Senken
|
Michael J. Senken
|
|
Chief Financial Officer
|
Date: November 13, 2012
|
/s/ Parker H. Petit
|
Parker H. Petit
|
|
Chief Executive Officer
|
Date: November 13, 2012
|
/s/ Michael J. Senken
|
Michael J. Senken
|
|
Chief Financial Officer
|
Acquisition of Surgical Biologics, LLC (Details) (USD $)
|
3 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 0 Months Ended | 1 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Jan. 05, 2011
|
Sep. 30, 2012
Trade names and trademarks [Member]
|
Jan. 05, 2011
Trade names and trademarks [Member]
|
Jan. 05, 2011
In-process research and development - liquid [Member]
|
Sep. 30, 2012
In-process research and development - other [Member]
|
Jan. 05, 2011
In-process research and development - other [Member]
|
Sep. 30, 2012
Customer Relationships [Member]
|
Sep. 30, 2012
Supplier Relationships [Member]
|
Sep. 30, 2012
Patents and know-how [Member]
|
Sep. 30, 2012
Licenses and permits [Member]
|
Jan. 05, 2011
Licenses and permits [Member]
|
Jan. 05, 2011
Surgical Biologics [Member]
|
Jul. 31, 2012
Surgical Biologics [Member]
|
Apr. 30, 2012
Surgical Biologics [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
Trade names and trademarks [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
In-process research and development - liquid [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
In-process research and development - other [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
Customer Relationships [Member]
|
Jan. 05, 2011
Surgical Biologics [Member]
Customer Relationships [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
Supplier Relationships [Member]
|
Jan. 05, 2011
Surgical Biologics [Member]
Supplier Relationships [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
Patents and know-how [Member]
|
Jan. 05, 2011
Surgical Biologics [Member]
Patents and know-how [Member]
|
Sep. 30, 2012
Surgical Biologics [Member]
Licenses and permits [Member]
|
|||||||||
Business Acquisition [Line Items] | |||||||||||||||||||||||||||||||||||||
Cash Paid | $ 500,000 | ||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, number of shares issuable (in shares) | 1,250,000 | ||||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, interest rate (in hundredths) | 4.00% | ||||||||||||||||||||||||||||||||||||
Common Stock issued (in shares) | 893,267 | 5,250,000 | 893,267 | 2,632,576 | |||||||||||||||||||||||||||||||||
Common Stock valued | 893,267 | 893,267 | 7,087,500 | ||||||||||||||||||||||||||||||||||
Common stock held in escrow (in shares) | 525,000 | ||||||||||||||||||||||||||||||||||||
Contingent Liability for Accrued Earn-Out Acquisition Consideration [Roll Forward] | |||||||||||||||||||||||||||||||||||||
Beginning balance | 7,410,503 | ||||||||||||||||||||||||||||||||||||
Common stock issued on earn-out | (3,185,223) | (3,185,223) | |||||||||||||||||||||||||||||||||||
(Gains) or losses included in earnings | 1,320,000 | 0 | 1,320,000 | 0 | 1,320,000 | ||||||||||||||||||||||||||||||||
Ending balance | (7,404,700) | 5,545,280 | |||||||||||||||||||||||||||||||||||
Number of Consecutive Trading Days | 20 days | ||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, conversion price (in dollars per share) | $ 1 | ||||||||||||||||||||||||||||||||||||
Convertible Promissory Note, stock price trigger (in dollars per share) | $ 1.75 | ||||||||||||||||||||||||||||||||||||
Repayments of Convertible Debt | 427,126 | 0 | 177,000 | ||||||||||||||||||||||||||||||||||
Actual purchase price allocated [Abstract] | |||||||||||||||||||||||||||||||||||||
Value of 5,250,000 shares issued at $1.35 per share | 7,087,500 | ||||||||||||||||||||||||||||||||||||
Cash paid at closing | 350,000 | ||||||||||||||||||||||||||||||||||||
Cash retained for working capital | 150,000 | ||||||||||||||||||||||||||||||||||||
Assumed Debt | 182,777 | ||||||||||||||||||||||||||||||||||||
Convertible Secured Promissory Note | 1,250,000 | ||||||||||||||||||||||||||||||||||||
Fair value of earn-out | 7,404,700 | (5,545,280) | |||||||||||||||||||||||||||||||||||
Total fair value of purchase price | 16,424,977 | ||||||||||||||||||||||||||||||||||||
Common Stock, share price (in dollars per share) | $ 1.35 | ||||||||||||||||||||||||||||||||||||
Tangible assets: | |||||||||||||||||||||||||||||||||||||
Debt-free working capital | 671,880 | 671,880 | |||||||||||||||||||||||||||||||||||
Other assets, net | 385 | ||||||||||||||||||||||||||||||||||||
Property, plant and equipment | 72,866 | ||||||||||||||||||||||||||||||||||||
Tangible assets purchased | 745,131 | ||||||||||||||||||||||||||||||||||||
Acquired Finite-Lived Intangible Assets [Line Items] | |||||||||||||||||||||||||||||||||||||
Acquired intangible assets | 13,000 | 3,520,000 | 241,000 | 5,530,000 | |||||||||||||||||||||||||||||||||
Weighted average useful life | 14 years | [1] | 14 years | [1] | 14 years | [1] | 3 years | [1] | 14 years | 14 years | 14 years | 3 years | |||||||||||||||||||||||||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||||||||||||||||||||||||||||||||||||
Acquired intangible asset | 1,008,000 | 2,160,000 | 25,000 | ||||||||||||||||||||||||||||||||||
Weighted average useful life | indefinite | [1] | indefinite | [1] | indefinite | indefinite | indefinite | ||||||||||||||||||||||||||||||
Total acquired intangible assets | 12,497,000 | ||||||||||||||||||||||||||||||||||||
Goodwill | 3,182,846 | ||||||||||||||||||||||||||||||||||||
Working capital [Abstract] | |||||||||||||||||||||||||||||||||||||
Cash | 33,583 | ||||||||||||||||||||||||||||||||||||
Prepaid Expenses | 2,738 | ||||||||||||||||||||||||||||||||||||
Accounts Receivable | 181,087 | ||||||||||||||||||||||||||||||||||||
License Receivable | 340,000 | ||||||||||||||||||||||||||||||||||||
Inventory | 347,106 | ||||||||||||||||||||||||||||||||||||
Accounts payable and accrued expenses | (196,101) | ||||||||||||||||||||||||||||||||||||
Deferred rent and customer deposits | (36,533) | ||||||||||||||||||||||||||||||||||||
Debt-free working capital | 671,880 | 671,880 | |||||||||||||||||||||||||||||||||||
Current portion of debt | (62,590) | ||||||||||||||||||||||||||||||||||||
Long-term debt | (21,187) | ||||||||||||||||||||||||||||||||||||
Line of credit | (99,000) | ||||||||||||||||||||||||||||||||||||
Net working capital | 489,103 | ||||||||||||||||||||||||||||||||||||
Deposits | 16,582 | ||||||||||||||||||||||||||||||||||||
Deferred rent (non-current) | $ (16,197) | ||||||||||||||||||||||||||||||||||||
|
Property and equipment (Tables)
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and equipment [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and equipment | Property and equipment consist of the following as of September 30, 2012 and December 31, 2011:
|
Debt (Details) (USD $)
|
9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 12 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | |||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
Convertible Senior Secured Promissory Notes [Member]
|
Jun. 30, 2011
Convertible Senior Secured Promissory Notes [Member]
|
Sep. 30, 2012
Convertible Senior Secured Promissory Notes [Member]
|
Sep. 30, 2011
Convertible Senior Secured Promissory Notes [Member]
|
Sep. 30, 2012
Contingent Warrants [Member]
|
Dec. 31, 2011
Contingent Warrants [Member]
|
Sep. 30, 2012
Contingent Warrants [Member]
Convertible Senior Secured Promissory Notes [Member]
|
Sep. 30, 2012
First Contingent Warrants [Member]
|
Dec. 31, 2011
First Contingent Warrants [Member]
|
Sep. 30, 2012
First Contingent Warrants [Member]
Convertible Senior Secured Promissory Notes [Member]
|
Sep. 30, 2012
Second Contingent Warrants [Member]
|
Dec. 31, 2012
Second Contingent Warrants [Member]
|
Sep. 30, 2012
Second Contingent Warrants [Member]
Convertible Senior Secured Promissory Notes [Member]
|
Feb. 28, 2012
Convertible Line of Credit with Related party [Member]
|
Mar. 31, 2011
Convertible Line of Credit with Related party [Member]
|
Jul. 31, 2012
Convertible Line of Credit with Related party [Member]
|
Jun. 30, 2011
Convertible Line of Credit with Related party [Member]
|
Sep. 30, 2012
Convertible Line of Credit with Related party [Member]
|
Sep. 30, 2012
Convertible Line of Credit with Related party [Member]
Contingent Warrants [Member]
|
Feb. 28, 2012
Convertible Line of Credit with Related party [Member]
Contingent Warrants [Member]
|
Jun. 30, 2011
Convertible Line of Credit with Related party [Member]
Contingent Warrants [Member]
|
Sep. 30, 2012
Convertible Line of Credit with Related party [Member]
First Contingent Warrants [Member]
|
Sep. 30, 2012
Convertible Line of Credit with Related party [Member]
Second Contingent Warrants [Member]
|
Jul. 31, 2012
Convertible Senior Secured Promissory Note [Member]
|
Sep. 30, 2012
Convertible Senior Secured Promissory Note [Member]
|
|||||||||||||||||||||||
Debt Facility [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Face Value of Note | $ 1,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Due date | Dec. 31, 2012 | [1] | |||||||||||||||||||||||||||||||||||||||||||||||
Annual Interest rate (in hundredths) | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Contingent warrants issued at inception (in shares) | 3,150,000 | [2] | 2,500,000 | [2] | 1,575,000 | [2] | 1,250,000 | [2],[3] | 1,575,000 | [2] | 1,250,000 | [2],[4] | 650,000 | [2] | 325,000 | [2],[5] | 325,000 | [2],[4] | |||||||||||||||||||||||||||||||
Warrants vested (in shares) | (1,250,000) | [3] | (1,575,000) | (325,000) | [5] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants voided (in shares) | (1,250,000) | [4] | 3,247,741 | (1,575,000) | (325,000) | [4] | |||||||||||||||||||||||||||||||||||||||||||
Contingent warrants outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price of warrants (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||
Additional interest payment (in hundredths) | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Term of warrants | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Per share value of consideration received by the holders of Common Stock in a change of control transaction, minimum (in dollars per share) | $ 1.75 | ||||||||||||||||||||||||||||||||||||||||||||||||
Percentage to purchase number of shares at one penny per share | 25.00% | 25.00% | |||||||||||||||||||||||||||||||||||||||||||||||
Amount of revenue that allows warrants to vest, maximum | 11,500,000 | 31,150,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Extension fee, rate (in hundredths) | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Extension fee | 65,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings during the period | 800,000 | 500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Contingent warrants issued (in shares) | 0 | 325,000 | 400,000 | 325,000 | 250,000 | ||||||||||||||||||||||||||||||||||||||||||||
Warrant and beneficial conversion value | 2,278,052 | 550,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Number of consecutive trading days | 10 days | 10 days | 10 days | 10 days | |||||||||||||||||||||||||||||||||||||||||||||
Closing trading price of company stock (in dollars per share) | $ 1.75 | $ 1.50 | $ 1.75 | $ 1.75 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||
Face value of note | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Total face value of notes | 6,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Due date | Dec. 31, 2013 | [6] | |||||||||||||||||||||||||||||||||||||||||||||||
Annual interest rate (in hundredths) | 5.00% | ||||||||||||||||||||||||||||||||||||||||||||||||
Contingent warrants issued at inception (in shares) | 3,150,000 | [2] | 2,500,000 | [2] | 1,575,000 | [2] | 1,250,000 | [2],[3] | 1,575,000 | [2] | 1,250,000 | [2],[4] | 650,000 | [2] | 325,000 | [2],[5] | 325,000 | [2],[4] | |||||||||||||||||||||||||||||||
Warrants vested (in shares) | (1,250,000) | [3] | (1,575,000) | (325,000) | [5] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants voided (in shares) | (1,250,000) | [4] | 3,247,741 | (1,575,000) | (325,000) | [4] | |||||||||||||||||||||||||||||||||||||||||||
Contingent warrants outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||
Weighted average exercise price of warrants (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price (in dollars per share) | $ 1.09 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||
Conversion price (in dollars per share) | $ 1.00 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrant and beneficial conversion value | 2,278,052 | 550,000 | |||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of Convertible Senior Secured Promissory Notes | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of Notes to Chairman of the Board and CEO | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Commitment to lend | 1,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Convertible debt, shares issuable if converted (in shares) | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Placement fee | 32,800 | ||||||||||||||||||||||||||||||||||||||||||||||||
Placement fee, warrants issued (in shares) | 42,400 | ||||||||||||||||||||||||||||||||||||||||||||||||
Fair value of placement fee warrants | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
Direct costs of sale of notes | $ 47,800 | ||||||||||||||||||||||||||||||||||||||||||||||||
|
Significant accounting policies
|
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2012
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant accounting policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant accounting policies | 2. Significant accounting policies Please see Note 2 to our Consolidated Financial Statements included in the Company's Form 10-K for the fiscal year ended December 31, 2011, for a description of all significant accounting policies. Reclassifications Certain amounts in the prior year financial statements have been reclassified to conform to the current year financial statement presentation. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Accounts Receivable Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customer's current creditworthiness, customer concentration, age of accounts receivable balance and general economic conditions that may affect the customer's ability to pay. The Company has $116,000 and $20,000 in the allowance for doubtful accounts as of September 30, 2012 and December 31, 2011, respectively. Actual customer collections could differ from estimates. The approximate provision during the nine months ended September 30, 2012 was $119,000, and there were approximately $23,000 of write-offs during the same period. Inventories Inventories are valued at the lower of actual cost or market, using the first-in, first-out ("FIFO") method. Work in process is calculated by estimating the number of units that will be successfully converted to finished goods, based upon a build-up in the stage of completion using estimated labor inputs for each stage and historical yields reduced by estimated usage for quality control testing. Idle facility expense, excessive spoilage, extra freight, and handling costs are expensed, as necessary, in cost of products sold and are not capitalized into inventories. Allocation of fixed production overheads is based on the normal capacity of production facilities. Goodwill and intangible assets Goodwill and intangible assets are tested at least annually for impairment, or more frequently if events or changes in circumstances indicate that the asset might be impaired. Intangible assets with finite useful lives are amortized into Selling, General and Administrative Expenses in the condensed consolidated statements of operations using the straight-line method over various periods depending upon the specific asset. Debt Instruments with Detachable Warrants and Beneficial Conversion Features According to ASC-470 Debt Instruments with Detachable Warrants, proceeds from the sale of debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital. Revenue Recognition The Company sells its products primarily through a combination of independent stocking distributors and representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilized distributors or ships product directly to the end user, it recognizes revenue upon shipment provided all revenue recognition criteria have been met. A portion of the Company's revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized. The Company recorded approximately $88,000 and $22,000 for net sales returns provisions for the three months ended September 30, 2012 and 2011, respectively, and there were approximately $135,000 and $0 of charges against the provision during the three months ended September 30, 2012 and 2011, respectively. The Company recorded approximately $233,000 and $159,000 for net sales returns provisions for the nine months ended September 30, 2012 and 2011, respectively, and there were approximately $161,000 and $102,000 of charges against the provision during the nine months ended September 30, 2012 and 2011, respectively. Fair value of financial instruments The carrying value of accounts payable and accrued expenses approximate their fair value due to the short-term nature of these liabilities. The fair value of our short term and long term convertible debt approximates $4,667,000 which represents the face value less the unamortized discount of any beneficial conversion feature plus accrued but unpaid interest at September 30, 2012. The fair value of warrants issued in conjunction with placement fees was approximately $9,000 which represents the face value less the unamortized discount of any beneficial conversion feature at September 30, 2012. Net loss per share Basic net loss per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method. For all periods presented, diluted net loss per share is the same as basic net loss per share, as the inclusion of equivalent shares from outstanding common stock options, warrants and convertible debt would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share:
The table above excludes all securities with contingencies including the earnout liability and contingent warrants. Recent Accounting Pronouncements The Company considers the applicability and impact of all ASU's. ASU's not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations. Goodwill The FASB issued updated authoritative guidance in September 2011 to amend previous guidance on the annual and interim testing of goodwill for impairment; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. The guidance provides entities with the option of first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined, on the basis of qualitative factors, that the fair value of the reporting unit is more likely than not less than the carrying amount, the two-step impairment test would still be required. Annual impairment tests are performed by the Company in the fourth quarter of each year. The adoption of this updated authoritative guidance did not have a significant impact on the Company's consolidated financial statements. Fair Value Measurements The FASB issued updated authoritative guidance in May 2011 to amend fair value measurements and related disclosures; the guidance became effective for MiMedx at the beginning of its 2012 fiscal year. This guidance relates to a major convergence project of the FASB and the International Accounting Standards Board to improve International Financial Reporting Standards ("IFRS") and GAAP. This guidance results in a consistent definition of fair value and common requirements for measurement of and disclosure about fair value between IFRS and GAAP. The guidance also changes some fair value measurement principles and enhances disclosure requirements related to activities in Level 3 of the fair value hierarchy. The adoption of this updated authoritative guidance had no impact on the Company's consolidated financial statements. Intangibles – Goodwill and Other In July 2012, the FASB issued an accounting standards update that gives an entity the option to first assess qualitative factors to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired. If, after assessing the totality of events and circumstances, an entity concludes that it is not more likely than not that the indefinite-lived intangible asset is impaired, then the entity is not required to take further action. This guidance will be effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, which will be the Company's fiscal year 2013, with early adoption permitted. The Company does not expect the adoption of the guidance will have a material impact on the Company's consolidated financial statements. Recently issued accounting pronouncements not yet adopted: In December 2011, the FASB issued new accounting guidance that will require entities to disclose information about instruments (including derivatives) and transactions eligible for offset in the statement of financial position or subject to an agreement similar to a master netting arrangement. These new provisions are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods, and should be applied retrospectively for all comparative periods presented. We do not expect this accounting standard to have an impact on our consolidated financial statements. |